印度颗粒获得美国FDA对特拉佐化片的批准,并计划在第一季度推出. Granules India receives US FDA approval for Trazodone Hydrochloride Tablets and plans to launch in Q1.

Granules India Limited获得美国FDA批准其盐酸曲唑酮片剂的ANDA应用，相当于Pragma Pharmaceuticals的Desyrel片剂，用于治疗成人重度抑郁症。 Granules India Limited secured US FDA approval for its ANDA application of Trazodone Hydrochloride Tablets, equivalent to Pragma Pharmaceuticals' Desyrel Tablets for treating major depressive disorder in adults. 这标志着Granules第65届ANDA批准, 目前美国Trazodone药片市场每年为128亿美元。 This marks Granules' 65th ANDA approval, and the current US market for Trazodone tablets is $128m annually. 公司计划本季度推出这一产品,目的是实现稳定的市场增长。 The company plans to launch the product this quarter, aiming for steady market growth.